Promoters, Foreign Institutional Investors and Domestic Institutional Investors increasing their holding stake in certain companies indicate a positive outlook on the company’s performance, management, and prospects, thereby leading to speculation of expected future growth and upcoming changes in the company.
Listed below are some of the stocks in which Promoters, Foreign Institutional Investors and Domestic Institutional Investors have increased their holding stake in Q2FY25
Remus Pharmaceuticals
Remus Pharmaceuticals Limited is engaged in the marketing and distribution of active pharmaceutical ingredients (API) and finished formulations of pharmaceutical drugs, it also provides technical consulting services to various distributors for the preparation of reports on the dossiers of the products.
With a market capitalization of Rs. 1,532 Crores, the shares of Remus Pharmaceuticals Limited were trading at Rs. 2,601 per equity share, up 1.15 percent from its previous day’s close price of Rs. 2,571.45.
As of Q2FY25, in Remus Pharmaceuticals Limited the Promoters, Foreign Institutional Investors and Domestic Institutional Investors have increased their holding by 0.18 percent, 0.16 percent and 0.04 percent respectively.
According to the latest shareholding data available for the Q2FY25 quarter, the company’s Promoters hold 70.84 percent stake, the Domestic Institutional Investors hold 0.77 percent and the Foreign Institutional Investors (FII) hold 3.16 percent.
Its revenue from operations grew by 41 percent from Rs. 45.03 Crores in FY23 to Rs. 63.5 Crores in FY24, accompanied by profits of Rs. 8.5 Crores to Rs. 16.82 Crores.
Himadri Speciality Chemical
Himadri Speciality Chemical Limited is engaged in designing and manufacturing speciality chemicals for textile, consumer care, oil and gas, chemical intermediates, and other industries.
With a market capitalization of Rs. 27,952 Crores, the shares of Himadri Speciality Chemical Limited were trading at Rs. 566.25 per equity share, down 0.40 percent from its previous day’s close price of Rs. 568.45.
As of Q2FY25, in Himadri Speciality Chemical Limited the Promoters, Foreign Institutional Investors and Domestic Institutional Investors have increased their holding by 0.58 percent, 0.08 percent and 1.32 percent respectively.
According to the latest shareholding data available for the Q2FY25 quarter, the company’s Promoters hold 50.78 percent stake, the Domestic Institutional Investors hold 3.59 percent and the Foreign Institutional Investors (FII) hold 5.24 percent.
Its revenue from operations grew by 13.18 percent from Rs. 1,005 Crores in Q2FY24 to Rs. 1,137 Crores in Q2FY25, accompanied by profits of Rs. 101 Crores to Rs. 136 Crores.
Suprajit Engineering
Suprajit Engineering Limited is engaged in the business of manufacturing and selling automotive parts and other components. Its product portfolio consists of Control cable mechanisms, instrument clusters, vehicle lighting, and allied motion control parts.
With a market capitalization of Rs. 6,728 Crores, the shares of Suprajit Engineering Limited were trading at Rs. 490.90 per equity share, up 2 percent from its previous day’s close price of Rs. 482.85.
As of Q2FY25, in Suprajit Engineering Limited the Promoters, Foreign Institutional Investors and Domestic Institutional Investors have increased their holding by 0.02 percent, 0.48 percent and 0.26 percent respectively.
According to the latest shareholding data available for the Q2FY25 quarter, the company’s Promoters hold 44.64 percent stake, the Domestic Institutional Investors hold 17.20 percent and the Foreign Institutional Investors (FII) hold 6.30 percent.
Its revenue from operations grew by 8.12 percent from Rs. 680 Crores in Q1FY24 to Rs. 735 Crores in Q1FY25, accompanied by profits of Rs. 33 Crores to Rs. 38 Crores.
Jai Balaji Industries
Jai Balaji Industries Limited is engaged in the business of manufacturing iron and steel products like sponge iron, pig iron, ductile iron pipe, and many more.
With a market capitalization of Rs. 19,313 Crores, the shares of Jai Balaji Industries Limited were trading at Rs. 1,058.55 per equity share, up 4.8 percent from its previous day’s close price of Rs. 1,008.15.
As of Q2FY25, in Remus Pharmaceuticals Limited the Promoters, Foreign Institutional Investors and Domestic Institutional Investors have increased their holding by 0.18 percent, 0.16 percent and 0.04 percent respectively.
According to the latest shareholding data available for the Q2FY25 quarter, the company’s Promoters hold 70.84 percent stake, the Domestic Institutional Investors hold 0.77 percent and the Foreign Institutional Investors (FII) hold 3.16 percent.
Its revenue from operations grew by 15.90 percent from Rs. 1,483 Crores in Q1FY24 to Rs. 1,718 Crores in Q1FY25, accompanied by profits of Rs. 170 Crores to Rs. 209 Crores.
Written by Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
